BFL-003

BFL-003 is a small molecule drug candidate developed by Psilera Bioscience for the treatment of treatment-resistant depression (TRD). As a product of Psilera's Bio-Forge platform, BFL-003 is a tryptamine derivative engineered to act as an agonist at the 5-HT2A serotonin receptor. The compound is designed to induce neuroplasticity and provide rapid-acting antidepressant effects, similar to traditional psychedelics like psilocybin, but with a modified pharmacological profile intended to minimize hallucinogenic side effects. This design aims to facilitate easier administration and broader patient access, potentially allowing for at-home use. According to company pipeline information, BFL-003 is being evaluated in Phase 3 clinical trials for TRD.